<br>        Inclusion Criteria:<br><br>          -  The patient is scheduled to undergo non-urgent PCI<br><br>          -  The patient is between 18 and 75 years of age (inclusive) and willing to comply with<br>             the protocol<br><br>          -  Women of childbearing potential must have a negative serum or urine pregnancy test<br>             within 24 hours of dosing. All patients must agree to use double barrier contraception<br>             during the study and for at least 4 weeks after their last dose.<br><br>          -  The patient or legally acceptable representative is able to read and give written<br>             informed consent and has signed an informed consent form approved by the<br>             Investigator's IRB/IEC<br><br>        Exclusion Criteria:<br><br>          -  Estimated or measured weight < 55 kg<br><br>          -  Acute non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation<br>             myocardial infarction (STEMI) within 7 days prior to PCI<br><br>          -  Chronic total occlusion or unprotected left main stenting<br><br>          -  Cardiogenic shock (systolic blood pressure < 90 mm Hg requiring vasopressor or<br>             hemodynamic support)<br><br>          -  Uncontrolled hypertension at the time of initial study drug administration defined as<br>             measured systolic blood pressure > 190 mm Hg or diastolic blood pressure > 108 mm Hg<br><br>          -  Planned staged PCI<br><br>          -  Planned surgery during the study period<br><br>          -  Planned GP IIb/IIIa use<br><br>          -  Patient has received a clopidogrel loading dose (=300 mg) within 7 days prior to<br>             randomization; patients on maintenance clopidogrel may be enrolled<br><br>          -  The planned administration of the study-specified clopidogrel loading dose is >12<br>             hours prior to PCI<br><br>          -  Administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g.,<br>             warfarin) within the 7 days prior to PCI<br><br>          -  Estimated creatinine clearance (e.g. Cockcroft-Gault) < 45 mL/min<br><br>          -  Anemia with hemoglobin level < 10 g/dL<br><br>          -  Thrombocytopenia (platelet count < 100,000/mm3)<br><br>          -  ALT and/or AST > 2.5 x the ULN or other indication of clinically significant hepatic<br>             dysfunction<br><br>          -  Facial or head trauma within the last 30 days<br><br>          -  Intraocular hemorrhage within the last 30 days<br><br>          -  Gastrointestinal bleeding within the last 30 days<br><br>          -  Active bleeding, or history of a bleeding disorder or known intracranial vascular<br>             malformation<br><br>          -  History of any prior ischemic stroke or TIA within the last 5 years or intracranial<br>             hemorrhage, neoplasm, or arteriovenous malformation<br><br>          -  Known allergy or contraindication to the components of PRT060128, aspirin, heparin,<br>             clopidogrel, glycoprotein IIb/IIIa inhibitors, or to any contrast media<br><br>          -  Participation in any investigational drug study within 30 days prior to enrollment.<br>             Participation in a device trial prior to enrollment is acceptable<br><br>          -  Prior participation in any study involving PRT060128<br><br>          -  Any condition which could interfere with, or the treatment for which might interfere<br>             with, the conduct of the study or which would, in the opinion of the Investigator,<br>             unacceptably increase the patient's risk by participating in the study. This would<br>             include, but is not limited to alcoholism, drug dependency or abuse, psychiatric<br>             disease, epilepsy or any unexplained blackouts<br>      ;<br>        Inclusion Criteria:<br><br>          -  The patient is scheduled to undergo non-urgent PCI<br><br>          -  The patient is between 18 and 75 years of age (inclusive) and willing to comply with<br>             the protocol<br><br>          -  Women of childbearing potential must have a negative serum or urine pregnancy test<br>             within 24 hours of dosing. All patients must agree to use double barrier contraception<br>             during the study and for at least 4 weeks after their last dose.<br><br>          -  The patient or legally acceptable representative is able to read and give written<br>             informed consent and has signed an informed consent form approved by the<br>             Investigator's IRB/IEC<br><br>        Exclusion Criteria:<br><br>          -  Estimated or measured weight < 55 kg<br><br>          -  Acute non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation<br>             myocardial infarction (STEMI) within 7 days prior to PCI<br><br>          -  Chronic total occlusion or unprotected left main stenting<br><br>          -  Cardiogenic shock (systolic blood pressure < 90 mm Hg requiring vasopressor or<br>             hemodynamic support)<br><br>          -  Uncontrolled hypertension at the time of initial study drug administration defined as<br>             measured systolic blood pressure > 190 mm Hg or diastolic blood pressure > 108 mm Hg<br><br>          -  Planned staged PCI<br><br>          -  Planned surgery during the study period<br><br>          -  Planned GP IIb/IIIa use<br><br>          -  Patient has received a clopidogrel loading dose (=300 mg) within 7 days prior to<br>             randomization; patients on maintenance clopidogrel may be enrolled<br><br>          -  The planned administration of the study-specified clopidogrel loading dose is >12<br>             hours prior to PCI<br><br>          -  Administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g.,<br>             warfarin) within the 7 days prior to PCI<br><br>          -  Estimated creatinine clearance (e.g. Cockcroft-Gault) < 45 mL/min<br><br>          -  Anemia with hemoglobin level < 10 g/dL<br><br>          -  Thrombocytopenia (platelet count < 100,000/mm3)<br><br>          -  ALT and/or AST > 2.5 x the ULN or other indication of clinically significant hepatic<br>             dysfunction<br><br>          -  Facial or head trauma within the last 30 days<br><br>          -  Intraocular hemorrhage within the last 30 days<br><br>          -  Gastrointestinal bleeding within the last 30 days<br><br>          -  Active bleeding, or history of a bleeding disorder or known intracranial vascular<br>             malformation<br><br>          -  History of any prior ischemic stroke or TIA within the last 5 years or intracranial<br>             hemorrhage, neoplasm, or arteriovenous malformation<br><br>          -  Known allergy or contraindication to the components of PRT060128, aspirin, heparin,<br>             clopidogrel, glycoprotein IIb/IIIa inhibitors, or to any contrast media<br><br>          -  Participation in any investigational drug study within 30 days prior to enrollment.<br>             Participation in a device trial prior to enrollment is acceptable<br><br>          -  Prior participation in any study involving PRT060128<br><br>          -  Any condition which could interfere with, or the treatment for which might interfere<br>             with, the conduct of the study or which would, in the opinion of the Investigator,<br>             unacceptably increase the patient's risk by participating in the study. This would<br>             include, but is not limited to alcoholism, drug dependency or abuse, psychiatric<br>             disease, epilepsy or any unexplained blackouts<br>      ;<br>        Inclusion Criteria:<br><br>          -  The patient is scheduled to undergo non-urgent PCI<br><br>          -  The patient is between 18 and 75 years of age (inclusive) and willing to comply with<br>             the protocol<br><br>          -  Women of childbearing potential must have a negative serum or urine pregnancy test<br>             within 24 hours of dosing. All patients must agree to use double barrier contraception<br>             during the study and for at least 4 weeks after their last dose.<br><br>          -  The patient or legally acceptable representative is able to read and give written<br>             informed consent and has signed an informed consent form approved by the<br>             Investigator's IRB/IEC<br><br>        Exclusion Criteria:<br><br>          -  Estimated or measured weight < 55 kg<br><br>          -  Acute non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation<br>             myocardial infarction (STEMI) within 7 days prior to PCI<br><br>          -  Chronic total occlusion or unprotected left main stenting<br><br>          -  Cardiogenic shock (systolic blood pressure < 90 mm Hg requiring vasopressor or<br>             hemodynamic support)<br><br>          -  Uncontrolled hypertension at the time of initial study drug administration defined as<br>             measured systolic blood pressure > 190 mm Hg or diastolic blood pressure > 108 mm Hg<br><br>          -  Planned staged PCI<br><br>          -  Planned surgery during the study period<br><br>          -  Planned GP IIb/IIIa use<br><br>          -  Patient has received a clopidogrel loading dose (=300 mg) within 7 days prior to<br>             randomization; patients on maintenance clopidogrel may be enrolled<br><br>          -  The planned administration of the study-specified clopidogrel loading dose is >12<br>             hours prior to PCI<br><br>          -  Administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g.,<br>             warfarin) within the 7 days prior to PCI<br><br>          -  Estimated creatinine clearance (e.g. Cockcroft-Gault) < 45 mL/min<br><br>          -  Anemia with hemoglobin level < 10 g/dL<br><br>          -  Thrombocytopenia (platelet count < 100,000/mm3)<br><br>          -  ALT and/or AST > 2.5 x the ULN or other indication of clinically significant hepatic<br>             dysfunction<br><br>          -  Facial or head trauma within the last 30 days<br><br>          -  Intraocular hemorrhage within the last 30 days<br><br>          -  Gastrointestinal bleeding within the last 30 days<br><br>          -  Active bleeding, or history of a bleeding disorder or known intracranial vascular<br>             malformation<br><br>          -  History of any prior ischemic stroke or TIA within the last 5 years or intracranial<br>             hemorrhage, neoplasm, or arteriovenous malformation<br><br>          -  Known allergy or contraindication to the components of PRT060128, aspirin, heparin,<br>             clopidogrel, glycoprotein IIb/IIIa inhibitors, or to any contrast media<br><br>          -  Participation in any investigational drug study within 30 days prior to enrollment.<br>             Participation in a device trial prior to enrollment is acceptable<br><br>          -  Prior participation in any study involving PRT060128<br><br>          -  Any condition which could interfere with, or the treatment for which might interfere<br>             with, the conduct of the study or which would, in the opinion of the Investigator,<br>             unacceptably increase the patient's risk by participating in the study. This would<br>             include, but is not limited to alcoholism, drug dependency or abuse, psychiatric<br>             disease, epilepsy or any unexplained blackouts<br>      ;<br>        Inclusion Criteria:<br><br>          -  The patient is scheduled to undergo non-urgent PCI<br><br>          -  The patient is between 18 and 75 years of age (inclusive) and willing to comply with<br>             the protocol<br><br>          -  Women of childbearing potential must have a negative serum or urine pregnancy test<br>             within 24 hours of dosing. All patients must agree to use double barrier contraception<br>             during the study and for at least 4 weeks after their last dose.<br><br>          -  The patient or legally acceptable representative is able to read and give written<br>             informed consent and has signed an informed consent form approved by the<br>             Investigator's IRB/IEC<br><br>        Exclusion Criteria:<br><br>          -  Estimated or measured weight < 55 kg<br><br>          -  Acute non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation<br>             myocardial infarction (STEMI) within 7 days prior to PCI<br><br>          -  Chronic total occlusion or unprotected left main stenting<br><br>          -  Cardiogenic shock (systolic blood pressure < 90 mm Hg requiring vasopressor or<br>             hemodynamic support)<br><br>          -  Uncontrolled hypertension at the time of initial study drug administration defined as<br>             measured systolic blood pressure > 190 mm Hg or diastolic blood pressure > 108 mm Hg<br><br>          -  Planned staged PCI<br><br>          -  Planned surgery during the study period<br><br>          -  Planned GP IIb/IIIa use<br><br>          -  Patient has received a clopidogrel loading dose (=300 mg) within 7 days prior to<br>             randomization; patients on maintenance clopidogrel may be enrolled<br><br>          -  The planned administration of the study-specified clopidogrel loading dose is >12<br>             hours prior to PCI<br><br>          -  Administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g.,<br>             warfarin) within the 7 days prior to PCI<br><br>          -  Estimated creatinine clearance (e.g. Cockcroft-Gault) < 45 mL/min<br><br>          -  Anemia with hemoglobin level < 10 g/dL<br><br>          -  Thrombocytopenia (platelet count < 100,000/mm3)<br><br>          -  ALT and/or AST > 2.5 x the ULN or other indication of clinically significant hepatic<br>             dysfunction<br><br>          -  Facial or head trauma within the last 30 days<br><br>          -  Intraocular hemorrhage within the last 30 days<br><br>          -  Gastrointestinal bleeding within the last 30 days<br><br>          -  Active bleeding, or history of a bleeding disorder or known intracranial vascular<br>             malformation<br><br>          -  History of any prior ischemic stroke or TIA within the last 5 years or intracranial<br>             hemorrhage, neoplasm, or arteriovenous malformation<br><br>          -  Known allergy or contraindication to the components of PRT060128, aspirin, heparin,<br>             clopidogrel, glycoprotein IIb/IIIa inhibitors, or to any contrast media<br><br>          -  Participation in any investigational drug study within 30 days prior to enrollment.<br>             Participation in a device trial prior to enrollment is acceptable<br><br>          -  Prior participation in any study involving PRT060128<br><br>          -  Any condition which could interfere with, or the treatment for which might interfere<br>             with, the conduct of the study or which would, in the opinion of the Investigator,<br>             unacceptably increase the patient's risk by participating in the study. This would<br>             include, but is not limited to alcoholism, drug dependency or abuse, psychiatric<br>             disease, epilepsy or any unexplained blackouts<br>